Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Wright

Internal Medicine Myrtle Beach, SC Doctor of Osteopathy

NPI 1164421525 CMS profile 279581

929 Medical Cir, Myrtle Beach, SC 29572

Open in the dashboard

General payments

$2,245

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Wright of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $2,245 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $395 14
2024 General $183 9
2023 General $115 7
2022 General $412 17
2021 General $530 16
2020 General $312 18
2019 General $297 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Wright
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Wright were reported at $395. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Wright Internal Medicine median Middle half National median
2019 $297 $159 $48–$570 $163
2020 $312 $119 $33–$402 $114
2021 $530 $135 $37–$521 $132
2022 $412 $141 $42–$496 $149
2023 $115 $149 $45–$519 $160
2024 $183 $154 $47–$537 $164
2025 $395 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $338 21 payments
  2. AstraZeneca Pharmaceuticals LP $225 8 payments
  3. Novo Nordisk Inc $173 8 payments
  4. Welch Allyn $168 1 payment
  5. Baxter Healthcare $168 1 payment
  6. Amarin Pharma Inc. $158 9 payments
  7. Phathom Pharmaceuticals, Inc. $121 1 payment
  8. Astellas Pharma US Inc $105 6 payments
  9. Mylan Specialty L.P. $104 6 payments
  10. Pfizer Inc. $75 5 payments
  11. Other $608 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,908 94 payments
  2. Debt forgiveness $337 2 payments
Products named General payments · program years 2019–2025
  1. None $168 1 payment
  2. UBRELVY $144 8 payments
  3. Ozempic $125 6 payments
  4. VOQUEZNA $121 1 payment
  5. RYBELSUS $120 6 payments
  6. Vascepa $120 7 payments
  7. BREZTRI $117 1 payment
  8. SYNTHROID $95 6 payments
  9. FARXIGA $92 6 payments
  10. MYRBETRIQ $71 4 payments
  11. Other $1,294 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

5,670

Median for Internal Medicine: 777

Drug cost

$314,344

Median for Internal Medicine: $73,373

Branded share of claims

12.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 83 $97,592
Farxiga Dapagliflozin Propanediol Brand 37 $42,384
Ozempic Semaglutide Brand 15 $26,579
Xarelto Rivaroxaban Brand 15 $23,408
Januvia Sitagliptin Phosphate Brand 12 $19,212
Invokana Canagliflozin Brand 12 $15,897
Icosapent Ethyl Generic 16 $5,397
Levothyroxine Sodium Generic 350 $4,157
Rosuvastatin Calcium Generic 300 $3,976
Synthroid Levothyroxine Sodium Brand 66 $3,633

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$143,698

Of which drugs: $3,316

Medicare patients

454

Average age 75

Services billed

2,675

231 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 24%
Diabetes 22%
Atrial fibrillation 16%
Cancer 13%
Chronic kidney disease 11%
Heart failure 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 73 73 $1,564
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 21 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $39
$39 — —
RYBELSUS
  • Novo Nordisk Inc $26
$26 — —
Ozempic
  • Novo Nordisk Inc $26
$26 15 —
SYNTHROID
  • AbbVie, Inc. $22
$22 66 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record